| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 13.801 | 0 | 1.404 | 3.886 | 2.407 | 0 | 0 |
| Total Income - EUR | - | - | - | 13.801 | 0 | 1.404 | 3.886 | 9.709 | 0 | 0 |
| Total Expenses - EUR | - | - | - | 7.418 | 11.444 | 8.644 | 6.278 | 10.179 | 192 | 6 |
| Gross Profit/Loss - EUR | - | - | - | 6.383 | -11.444 | -7.241 | -2.392 | -470 | -192 | -6 |
| Net Profit/Loss - EUR | - | - | - | 5.969 | -11.444 | -7.283 | -2.508 | -761 | -192 | -6 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Pharma Gmp Audit Consulting S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 2 | 16.431 | 12.172 | 8.042 | 0 | 0 | 0 |
| Current Assets | - | - | - | 8.623 | 42 | 14 | 708 | 17 | -14 | -19 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 1.200 | 0 | 0 | -1 | 0 | 0 | 0 |
| Cash | - | - | - | 7.423 | 42 | 14 | 709 | 17 | -14 | -19 |
| Shareholders Funds | - | - | - | 6.012 | -5.548 | -12.726 | -14.952 | -15.759 | -15.903 | -15.820 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 2.613 | 22.022 | 24.912 | 23.702 | 15.776 | 15.890 | 15.801 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Pharma Gmp Audit Consulting S.r.l.